TMS Co

TMS Co EBITDA Growth YoY

The Year-over-Year EBITDA Growth of TMS Co (4891.T) as of Nov 3, 2026 is 7.87 %. In the previous year, Year-over-Year EBITDA Growth was 3.21 % — a change of 145.38% (higher).

EBITDA Growth YoY

7.87 %

YoY

145.38%

Last updated:

Year-over-Year EBITDA Growth of TMS Co is 2026 7.87 % . Year-over-Year EBITDA Growth of TMS Co was 2025 3.21 % . It decreases by 145.38% higher compared to the previous year.

The TMS Co EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2022
258.39 JPY
Jan 1, 2023
-145.34 JPY
Jan 1, 2024
-82.10 JPY
Jan 1, 2025
3.21 JPY
Jan 1, 2026
7.87 JPY
The TMS Co EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
7.87 %+145.38%
3.21 %-103.91%
-82.10 %-43.51%
-145.34 %-156.25%
258.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Year-over-Year EBITDA Growth of TMS Co is 7.87 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth TMS Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's TMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — TMS Co

All Key Metrics — TMS Co